Two groundbreaking medications, Leqembi (lecanemab) and Kisunla (donanemab), are now available to slow Alzheimer's progression. These drugs represent the first effective treatments targeting the disease's underlying cause rather than just symptoms.

Both medications work by removing amyloid plaques from the brain through antibody treatment. Leqembi targets smaller amyloid protofibrils, while Kisunla binds to larger amyloid plaques. They're administered through IV infusion, unlike traditional oral Alzheimer's medications.

Treatment Schedule:

• Leqembi: Every 2 weeks for 18 months, then monthly
• Kisunla: Monthly until amyloid levels decrease (confirmed by PET scan)

Important Considerations:

1. Effectiveness:

• Modestly slows disease progression
• Most effective in early-stage Alzheimer's
• May prevent cognitive decline if started early

2. Side Effects:

• Mild: Flu-like symptoms, treatable with over-the-counter medications
• Serious: ARIA (brain swelling or bleeding)
• Higher risk for patients with cardiovascular conditions
• Particularly dangerous for patients on blood thinners

3. Practical Factors:

• Annual cost exceeds $25,000
• Requires regular IV administration
• Needs ongoing monitoring through brain scans
• Not suitable for all Alzheimer's patients

This treatment represents a significant breakthrough in Alzheimer's care, though patients should carefully weigh benefits against risks and costs. Consultation with a qualified neurologist is essential to determine suitability for treatment.

Related Articles

Previous Articles